

***Inhibition of the sodium-translocating NADH-ubiquinone oxidoreductase [Na<sup>+</sup>-NQR] decreases cholera toxin production in Vibrio cholerae O1 at the late exponential growth phase***

The Faculty of Oregon State University has made this article openly available.  
Please share how this access benefits you. Your story matters.

<b>Citation</b>	Minato, Y., Fassio, S. R., Reddekopp, R. L., & Häse, C. C. (2014). Inhibition of the sodium-translocating NADH-ubiquinone oxidoreductase [Na <sup>+</sup> -NQR] decreases cholera toxin production in <i>Vibrio cholerae</i> O1 at the late exponential growth phase. <i>Microbial Pathogenesis</i> , 66, 36-39. doi:10.1016/j.micpath.2013.12.002
<b>DOI</b>	10.1016/j.micpath.2013.12.002
<b>Publisher</b>	Elsevier
<b>Version</b>	Accepted Manuscript
<b>Terms of Use</b>	<a href="http://cdss.library.oregonstate.edu/sa-termsfuse">http://cdss.library.oregonstate.edu/sa-termsfuse</a>

1 Inhibition of the sodium-translocating NADH-ubiquinone oxidoreductase [Na<sup>+</sup>-NQR]  
2 decreases cholera toxin production in *Vibrio cholerae* O1 at the late exponential growth  
3 phase.

4 Yusuke Minato<sup>1,a</sup>, Sara R. Fassio<sup>2</sup>, Rylan L. Reddekopp<sup>2,3</sup>, and Claudia C. Häse<sup>1,2,3\*</sup>

5  
6 Department of Biomedical Sciences, College of Veterinary Medicine<sup>1</sup>,  
7 Department of Microbiology<sup>2</sup> and Molecular and Cellular Biology Graduate Program<sup>3</sup>,  
8 College of Science, Oregon State University,  
9 Corvallis, OR 97331, USA.

10

11 <sup>a</sup> present address; Department of Microbiology, University of Minnesota, 420 Delaware  
12 St. SE, Minneapolis, MN 55455, USA.

13

14 \*Corresponding author.

15

16 Mailing address: 105 Magruder Hall, Corvallis OR 97331-4801, USA

17 Phone: (541) 737-7001, Fax: (541) 737-2730,

18 E-mail: hasec@science.oregonstate.edu

19

20 Running Title: Na<sup>+</sup>-NQR and CT production

21

22 Key Words: anti-virulence drug; *Vibrio cholerae*; Na<sup>+</sup>-NQR; electron transport chain;  
23 cholera toxin

## Abstract

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

Two virulence factors produced by *Vibrio cholerae*, cholera toxin (CT) and toxin-correlated pilus (TCP), are indispensable for cholera infection. ToxT is the central regulatory protein involved in activation of CT and TCP expression. We previously reported that lack of a respiration-linked sodium-translocating NADH-ubiquinone oxidoreductase (Na<sup>+</sup>-NQR) significantly increases *toxT* transcription. In this study, we further characterized this link and found that Na<sup>+</sup>-NQR affects *toxT* expression only at the early-log growth phase, whereas lack of Na<sup>+</sup>-NQR decreases CT production after the mid-log growth phase. Such decreased CT production was independent of *toxT* and *ctxB* transcription. Supplementing a respiratory substrate, L-lactate, into the growth media restored CT production in the *nqrA-F* mutant, suggesting that decreased CT production in the Na<sup>+</sup>-NQR mutant is dependent on electron transport chain (ETC) activity. This notion was supported by the observations that two chemical inhibitors, a Na<sup>+</sup>-NQR specific inhibitor 2-n-Heptyl-4-hydroxyquinoline N-oxide (HQNO) and a succinate dehydrogenase (SDH) inhibitor, thenoyltrifluoroacetone (TTFA), strongly inhibited CT production in both classical and El Tor biotype strains of *V. cholerae*. Accordingly, we propose the main respiratory enzyme of *V. cholerae*, as a potential drug target to treat cholera because human mitochondria do not contain Na<sup>+</sup>-NQR orthologs.

## 46 **1. Introduction**

47 *Vibrio cholerae* is the etiological agent of cholera, a life-threatening diarrheal  
48 disease. Toxin-coregulated pilus (TCP) and cholera toxin (CT) are critical determinants  
49 of the pathogenicity of *V. cholerae*. TCP is a Type IV pilus that is required for  
50 colonization in the small intestine [1], whereas CT is a secreted enterotoxin responsible  
51 for inducing severe watery diarrhea, a hallmark feature of cholera [2]. The expression  
52 levels of TCP and CT are positively regulated by an AraC-type transcriptional regulator,  
53 ToxT [3].

54 The sodium-translocating NADH–ubiquinone oxidoreductase ( $\text{Na}^+$ -NQR) is a  
55 unique redox-driven sodium pump and is found in the electron transport chain (ETC) of  
56 a number of pathogenic and marine bacteria [4].  $\text{Na}^+$ -NQR is predicted to play a vital  
57 role in the ETC of these organisms, including *V. cholerae*, that do not possess an  
58 ortholog of the mitochondrial Complex I, which is typically the main ETC-linked NADH-  
59 dehydrogenase (<http://gsc.icvi.org/projects/msc/vibrio/>). It is well known that the genes  
60 encoding NQR are strongly repressed at anaerobic conditions [5,6]. Since some parts  
61 of the small intestine are anaerobic, one might speculate that lack of  $\text{Na}^+$ -NQR does not  
62 affect *V. cholerae* O1 virulence. However, a previous study revealed that  $\text{Na}^+$ -NQR is  
63 essential for *V. cholerae* O1 colonization in the small intestine of mice and in acid  
64 tolerance response (ATR) [7]. This suggested that  $\text{Na}^+$ -NQR is essential for *V. cholerae*  
65 O1 virulence and could be used as a molecular target to develop new therapeutic  
66 treatments for cholera. In this study, we further aimed to examine the link between  $\text{Na}^+$ -  
67 NQR and virulence factor production as a first step to evaluate  $\text{Na}^+$ -NQR as a molecular  
68 target for anti-cholera drug development.

## 69 **2. Materials and Methods**

70 *2.1. Bacterial strains, plasmids and media.* *V. cholerae* O1 classical biotype  
71 strains, O395N1 and CA401, their  $\Delta nqrA-F$  mutant strains, and El Tor biotype strain,  
72 N16961, were used in this study. The  $\Delta nhaA$  mutant, the  $\Delta nhaB$  mutant and the  
73  $\Delta mrpA-F$  mutant strains of *V. cholerae* O395N1 (Quinn et. al. unpublished) were also  
74 used in this study. All bacterial strains were kept at -80°C in 20% glycerol stocks. The  
75 classical biotype strains were grown overnight in Luria-Bertani (LB) medium (Difco) at  
76 37°C, washed, diluted to OD<sub>600</sub> = 0.05 in LB (initial pH 6.5), and grown at 30°C. The pH  
77 of the LB medium was adjusted to pH 6.5 with HCl. The El Tor biotype strain, N16961,  
78 was grown overnight in LB medium at 37°C and then grown in Yeast Extract Peptone  
79 water (YEP) as described previously (i.e., AKI growth conditions) [8]. HQNO and TTFA  
80 were added at 2.5 µM. L-lactate was added at 40 mM. L-lactate was also added to the  
81 pre-cultures to induce L-lactate dehydrogenase activity. Streptomycin was  
82 supplemented at 100 µg/ml.

83 *2.2 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)*  
84 *analysis.* Cells of *V. cholerae* O1 grown in LB (initial pH 6.5) at 30°C for 2, 4, 6, and 8  
85 hours were treated with RNA Protect Bacteria Reagent (Qiagen). RNA was extracted  
86 using the QIAGEN RNeasy Mini Kit (Qiagen) and treated with TURBO DNA-free™ Kit  
87 (Invitrogen). Primers used for qRT-PCR are 5Vc16SrRNAqRT:  
88 GATCATGGCTCAGATTGAACG, 3Vc16SrRNAqRT: TCGCCACCCAAGGAACA,  
89 5VcToxTqRT: GCTGTCCTTTCTGAAGTGGTAAATG, 3VCToxTqRT:  
90 TTCTACTTTTCGAGAAGAACCCTGAA, 5VcCtxBqRT: AGCGATTGAAAGGATGAAGGA,  
91 3VcCtxBqRT: CGCATGAGGCGTTTTATTATTC, 5VcTcpAqRT:

92 CGTAATGCAGCAGCTAATAAAGCA, 3VcTcpAqRT:  
93 GGAACATATCACCGACACTGGTAA. Real-time qRT-PCR reactions were performed  
94 using the SuperScript<sup>®</sup> III Platinum<sup>®</sup> SYBR<sup>®</sup> Green One-Step qRT-PCR Kit (Invitrogen)  
95 and an ABI PRISM 7500 FAST Sequence Detection System (Applied Biosystems) at  
96 the Center for Genome Research and Biocomputing Core Laboratory at Oregon State  
97 University.

98 *2.3 Measurements of CT production.* CT production was determined by GM<sub>1</sub>-  
99 based enzyme linked immunosorbent assays (CT-ELISA) essentially as described [9].  
100 In brief, CT-ELISA was performed using a cholera toxin-specific monoclonal antibody  
101 (Abcam) and Goat-Anti-Mouse (GAM)-HRP Conjugated antibodies (Bio-Rad). An HRP  
102 Substrate kit (Bio-Rad) was used to detect the HRP activity and the plates were read at  
103 415 nm on an iMark microplate reader (Bio-Rad). The amount of CT was quantified  
104 using known amounts of purified cholera toxin B subunit (Sigma) as the standard.

### 105 **3. Results**

106 *3.1 Growth phase dependent effects of Na<sup>+</sup>-NQR on toxT expression and cholera*  
107 *toxin production.* Because we previously reported that Na<sup>+</sup>-NQR affects *toxT*  
108 transcription [10], we monitored the growth and virulence gene expressions using *V.*  
109 *cholerae* parent and isogenic O395N1Δ*nqrA-F* mutant strains cultured under conditions  
110 typically used for *in vitro* induction of virulence gene expression [LB (initial pH 6.5) at  
111 30°C] [9]. Initially, both strains displayed very similar growth rates, although the  
112 O395N1Δ*nqrA-F* mutant transitioned to a slower growth rate starting approximately from  
113 the mid- to late-exponential growth phase (Fig. 1A). Measurements of *toxT*, *ctxB* and  
114 *tcpA* expression levels in the O395N1Δ*nqrA-F* mutant were compared with the parent

115 strain by qRT-PCR. Consistent with our previous findings [10], the O395N1 $\Delta nqrA-F$   
116 mutant showed higher *toxT*, *ctxB* and *tcpA* expression levels than the isogenic parent  
117 strain, however, this effect was only observed at the very early exponential growth  
118 phase (2 hr growth) (Fig. 1B). In agreement with the gene expression data,  
119 extracellular CT levels in the O395N1 $\Delta nqrA-F$  mutant were higher than in the parent  
120 strain at the early exponential growth phase (Fig. 1C). In contrast, the O395N1 $\Delta nqrA-F$   
121 mutant showed significantly lower extracellular CT levels compared to the parent strain  
122 at the late exponential growth phase (Fig. 1D), even though transcriptional levels of the  
123 *toxT* and *ctxB* genes were similar in both strains during late exponential growth phase  
124 (6 hr and 8 hr growth) (Fig. 1B). Similar extracellular CT level patterns were also  
125 observed in another *V. cholerae* O1 classical strain, CA401 and its  $\Delta nqrA-F$  deletion  
126 derivative (Fig. 1C and 1D).

127         The autoagglutination phenotype is correlated with TCP production [11]. Here,  
128 we observed that both the O395N1 $\Delta nqrA-F$  and the CA401 $\Delta nqrA-F$  strains did not show  
129 a full autoagglutination phenotype after overnight growth in LB (initial pH 6.5) at 30°C,  
130 whereas both of the parent strains did (data not shown). This suggested that the lack of  
131 functional Na<sup>+</sup>-NQR also negatively affects overall TCP production, although *tcpA*  
132 transcription levels were comparable between the O395N1 parent and  $\Delta nqrA-F$  mutant  
133 strains (Fig. 1B).

134         **3.2 Other sodium-translocating enzymes do not affect CT production.** We next  
135 aimed to gain a better understanding of the effects of loss of Na<sup>+</sup>-NQR on CT  
136 production in *V. cholerae* O1. The Na<sup>+</sup>-NQR has two major functions: it is a primary  
137 sodium pump and a major component in the *V. cholerae* ETC [4]. To examine the role

138 of sodium pumping, we investigated the effects of loss of other sodium-translocating  
139 enzymes on CT production. Genetic inactivation of various sodium/proton antiporters,  
140 including NhaA, NhaD, and Mrp, did not have any effects on extracellular CT levels  
141 (data not shown), suggesting that loss of sodium pumping *per se* does not affect  
142 extracellular CT levels. Furthermore, we noted that the addition of L-lactate into the  
143 growth media “rescued” extracellular CT levels in the O395N1 $\Delta nqrA-F$  mutant to the  
144 levels observed in the parent strain (Fig. 2). Since L-lactate is a respiration substrate  
145 for the L-lactate-ubiquinone oxidoreductase activity, these data suggested that reduced  
146 ETC activity might be responsible for the decreased extracellular CT levels in the *V.*  
147 *cholerae* O1 Na<sup>+</sup>-NQR mutants.

148         **3.3 ETC inhibitors inhibit CT production.** To further investigate the role of ETC  
149 on CT production, we investigated the effects of the Na<sup>+</sup>-NQR-specific inhibitor, 2-n-  
150 Heptyl-4-hydroxyquinoline N-oxide (HQNO), and a succinate dehydrogenase (SDH)  
151 inhibitor, thenoyltrifluoroacetone (TTFA), on CT production. In agreement with the data  
152 from the O395N1 $\Delta nqrA-F$  and the CA401 $\Delta nqrA-F$  strains, HQNO inhibited CT  
153 production in two classical biotype wild-type strains of *V. cholerae* O1, O395N1 and  
154 CA401 (Fig. 3). Similarly, TTFA also inhibited CT production in these two strains.

155         To investigate whether ETC inhibitors also inhibited CT production in an El Tor  
156 biotype strain, we tested the effect of these chemicals on CT production of *V. cholerae*  
157 N16961. When grown under AKI conditions, a specific growth condition for the El Tor  
158 biotype strain to produce measurable CT *in vitro* [8], the *V. cholerae* N16961 strain  
159 produced detectable amounts of CT as expected. However, addition of HQNO or TTFA  
160 to the growth media strongly inhibited CT production of *V. cholerae* N16961 (Fig. 3).



161 These data suggested that the ETC activities are essential for CT production in both  
162 classical and El Tor biotype strains.

#### 163 **4. Discussion**

164 In this study, we found that inhibition of *V. cholerae* O1 Na<sup>+</sup>-NQR inhibited CT  
165 production. Further studies revealed that such decreased CT production is not a Na<sup>+</sup>-  
166 NQR specific effect and inhibition of other ETC components, such as SDH, also  
167 inhibited CT production. In general, many of the ETC inhibitors are highly toxic to  
168 human cells due to their inhibitory effect on the mitochondrial ETC [12]. Thus, for future  
169 antimicrobial drug development, it is important to target bacterial ETC components that  
170 do not exist in the human mitochondrial ETC. Comparison of the *V. cholerae* and the  
171 human mitochondrial ETCs revealed that Na<sup>+</sup>-NQR, two *bd*-type oxidases and three  
172 ETC-linked dehydrogenases (DHs) are present in *V. cholerae* that are not in found the  
173 human mitochondrial ETC (Fig. 4). Thus, apart from Na<sup>+</sup>-NQR, such *bd*-type oxidases  
174 and ET- linked DHs might also be potential drug targets to inhibit CT and TCP  
175 production in *V. cholerae* O1. We are currently investigating this possibility.

176 We found that the *V. cholerae* O1  $\Delta nqrA$ -F mutant showed growth defects when  
177 grown in LB media. Similar growth kinetics have previously been observed for an  
178 *Escherichia coli* Complex I (NADH:ubiquinone oxidoreductase, *nuoB*) mutant in tryptone  
179 medium [13]. Furthermore, like the *E. coli* *nuoB* mutant [13], the O395N1 $\Delta nqrA$ -F  
180 mutant showed decreased acetate utilization [14], suggesting a depletion of available  
181 NAD<sup>+</sup>. Taken together with the fact that the *V. cholerae* genome does not encode *nuo*  
182 genes, these observations suggested that Na<sup>+</sup>-NQR is the main ETC-linked NADH  
183 dehydrogenase in *V. cholerae*. Similar to *V. cholerae*, some other important pathogenic

184 bacteria, such as *Vibrio parahaemolyticus*, *Vibrio vulnificus*, and *Haemophilus influenza*  
185 do not have Nuo but instead have Na<sup>+</sup>-NQR, suggesting that Na<sup>+</sup>-NQR plays major  
186 roles in the ETC in these pathogenic bacteria. On the other hand, some pathogenic  
187 bacteria, such as *Yersinia pestis* and *Pseudomonas aeruginosa*, have both Na<sup>+</sup>-NQR  
188 and Nuo. In contrast to *V. cholerae*, the *Y. pestis* and *P. aeruginosa* strains that lack  
189 functional Na<sup>+</sup>-NQR did not show growth defects when grown in LB media (Minato et.al.  
190 unpublished data), suggesting that lack of Na<sup>+</sup>-NQR significantly affects bacterial ETC  
191 activity only when Nuo is absent. It is also important to note that lack of Na<sup>+</sup>-NQR does  
192 not affect *Y. pestis* virulence [15].

193         The temporal increase in *toxT* expression in the *V. cholerae* O1  $\Delta nqrA-F$  mutant  
194 might be caused by a combination of multiple factors. Our recent study suggested that  
195 lack of Na<sup>+</sup>-NQR increases *toxT* expression via affecting acetyl-CoA [14]. Interestingly,  
196 it was known that intracellular acetyl-CoA levels are higher only at the early-log growth  
197 in *E. coli* [16]. Thus, it is tempting to speculate that lack of Na<sup>+</sup>-NQR increases *toxT*  
198 expression only at the early-log growth phase because intracellular acetyl-CoA levels  
199 are high only at the early-log growth phase.

200         The overall CT production of the *V. cholerae* O1  $\Delta nqrA-F$  mutant was much less  
201 than the parent strain. Since *ctxB* gene expressions in the  $\Delta nqrA-F$  mutant were similar  
202 to the parent strain after the mid-log growth phase, these data indicated that lack of  
203 Na<sup>+</sup>-NQR has a negative impact on CT levels via affecting either translation or secretion.  
204 Future studies will be necessary for understanding the molecular mechanism of Na<sup>+</sup>-  
205 NQR mediated CT production.

206 In summary, our data raised the possibility of using Na<sup>+</sup>-NQR as a potential novel  
207 molecular target for the development of new therapeutic interventions against cholera  
208 for several reasons: 1) Na<sup>+</sup>-NQR appears to be the major ETC-linked enzyme in *V.*  
209 *cholerae*; 2) genetic or chemical inactivation of Na<sup>+</sup>-NQR significantly diminishes the  
210 overall levels of CT; 3) the *V. cholerae*  $\Delta nqrA-F$  mutant has a severe to moderate  
211 growth defect; 4) the *V. cholerae*  $\Delta nqrA-F$  mutant was previously found to be attenuated  
212 in a mouse model [7]; and 5) Na<sup>+</sup>-NQR has no orthologs in the human cells. Because  
213 inhibition of Na<sup>+</sup>-NQR does not kill bacteria, targeting Na<sup>+</sup>-NQR would be expected to  
214 produce less pressure to evolve bacterial resistance compared to the traditional  
215 antimicrobial agents, similar to the other “anti-virulence” drug strategies [17].

216

217

### Acknowledgments

218 We thank Erin J. Lind, Frances M. Biel and Dr. Alisha M. Aagesen for their  
219 excellent technical assistances. This research was supported by grants from the  
220 National Institutes of Health to C.C.H. [AI-063121-02]. S.R.F was partially supported by  
221 the OSU Undergraduate Research, Innovation, Scholarship & Creativity (URISC) fund  
222 and the OSU Howard Hughes Medical Institute Summer Undergraduate Research  
223 Program.

224

## References

- 225  
226
- 227 [1] Taylor RK, Miller VL, Furlong DB, Mekalanos JJ. Use of *phoA* gene fusions to  
228 identify a pilus colonization factor coordinately regulated with cholera toxin. Proc  
229 Natl Acad Sci USA 1987;84:2833-7.
- 230 [2] Vanden Broeck D, Horvath C, De Wolf MJ. *Vibrio cholerae*: cholera toxin. Int J  
231 Biochem Cell Biol 2007;39:1771-5.
- 232 [3] DiRita VJ, Parsot C, Jander G, Mekalanos JJ. Regulatory cascade controls  
233 virulence in *Vibrio cholerae*. Proc Natl Acad Sci USA 1991;88:5403-7.
- 234 [4] Häse CC, Fedorova ND, Galperin MY, Dibrov PA. Sodium ion cycle in bacterial  
235 pathogens: evidence from cross-genome comparisons. Microbiol Mol Biol Rev  
236 2001;65:353-70.
- 237 [5] Fadeeva MS, Yakovtseva EA, Belevich GA, Bertsova YV, Bogachev AV.  
238 Regulation of expression of Na<sup>+</sup>-translocating NADH:quinone oxidoreductase  
239 genes in *Vibrio harveyi* and *Klebsiella pneumoniae*. Arch Microbiol  
240 2007;188:341-48.
- 241 [6] Isabella VM, Clark VL. Deep sequencing-based analysis of the anaerobic  
242 stimulon in *Neisseria gonorrhoeae*. BMC Genomics 2011;12:51.
- 243 [7] Merrell DS, Hava DL, Camilli A. Identification of novel factors involved in  
244 colonization and acid tolerance of *Vibrio cholerae*. Mol Microbiol 2002;43:1471-  
245 91.
- 246 [8] Iwanaga M, Kuyyakanond T. Large production of cholera toxin by *Vibrio cholerae*  
247 O1 in yeast extract peptone water. J Clin Microbiol 1987;25:2314-6.

- 248 [9] Gardel CL, Mekalanos JJ. Regulation of cholera toxin by temperature, pH, and  
249 osmolarity. *Methods Enzymol* 1994;235:517-26.
- 250 [10] Häse CC, Mekalanos JJ. Effects of changes in membrane sodium flux on  
251 virulence gene expression in *Vibrio cholerae*. *Proc Natl Acad Sci USA*  
252 1999;96:3183-7.
- 253 [11] Chiang SL, Taylor RK, Koomey M, Mekalanos JJ. Single amino acid substitutions  
254 in the N-terminus of *Vibrio cholerae* TcpA affect colonization, autoagglutination,  
255 and serum resistance. *Mol Microbiol* 1995;17:1133-42.
- 256
- 257 [12] Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation  
258 system. *Annu Rev Biochem* 1985;54:1015-69.
- 259 [13] Prüss BM, Nelms JM, Park C, Wolfe AJ. Mutations in NADH:ubiquinone  
260 oxidoreductase of *Escherichia coli* affect growth on mixed amino acids. *J*  
261 *Bacteriol* 1994;176:2143-50.
- 262 [14] Minato Y, Fassio SR, Wolfe AJ, Häse CC. Central metabolism controls  
263 transcription of a virulence gene regulator in *Vibrio cholerae*. *Microbiology*  
264 2013;159:792-802.
- 265 [15] Minato Y, Ghosh A, Faulkner WJ, Lind EJ, Schesser Bartra S, Plano GV, et al.  
266 Na<sup>+</sup>/H<sup>+</sup> antiport is essential for *Yersinia pestis* virulence. *Infect Immun*  
267 2013;81:3163-72.
- 268 [16] Wolfe AJ. The acetate switch. *Microbiol Mol Biol Rev* 2005;69:12-50.
- 269 [17] Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated  
270 disease. *Nat Rev Drug Discov* 2010;9:117-28.

271

## Figure legends

272

273 Figure 1. Growth-phase dependent virulence gene expression and CT production.  
274 Overnight cultures of *V. cholerae* O395N1, CA401, and their respective isogenic  $\Delta nqrA$ -  
275 *F* mutants were washed and diluted in LB (initial pH 6.5) to OD<sub>600</sub> = 0.05 and shaken in  
276 LB (initial pH 6.5) at 30°C. All experiments were repeated three times. The error bars  
277 indicate standard deviations. (A) Bacterial growth was measured by OD<sub>600</sub>. (B). Total  
278 RNA was extracted and analyzed by qRT-PCR. Gene expression levels were  
279 normalized between the samples by using 16S ribosomal RNA. (C, D) The cell-free  
280 culture supernatants were prepared from 4hr growth (C) and 8hr growth (D) and  
281 assayed for CT production by CT-ELISA. P values were calculated by Student's t test  
282 and \* indicates P < 0.05.

283

284 Figure 2. The effects of L-lactate on CT production. Overnight cultures of *V. cholerae*  
285 O395N1 and its respective isogenic  $\Delta nqrA$ -*F* mutant were washed and diluted in LB  
286 (initial pH 6.5) to OD<sub>600</sub> = 0.05 and shaken in LB (initial pH 6.5) at 30°C for overnight.  
287 The cell-free culture supernatants were prepared after growth and assayed for CT  
288 production by CT-ELISA. All experiments were repeated at least three times. The error  
289 bars indicate standard errors. P values were calculated by one-way ANOVA followed by  
290 post hoc comparisons using the Bonferroni test and \* indicates statistical significance  
291 (P < 0.05).

292 Figure 3. The effects of HQNO and TTFA on CT production. Overnight cultures of *V.*  
293 *cholerae* O395N1 and CA401 were washed and diluted in LB (initial pH 6.5) to the initial

294 OD<sub>600</sub> = 0.05 and cultured in LB (initial pH 6.5) at 30°C for 8hr. Cultures of *V. cholerae*  
295 N16961 were grown in YEP medium under AKI conditions. HQNO and TTFA were  
296 added at 2.5 μM. The cell-free culture supernatants were prepared after growth and  
297 assayed for CT production by CT-ELISA. All experiments were repeated three times.  
298 The error bars indicate standard errors. P values were calculated by one-way ANOVA  
299 followed by post hoc Bonferroni test and \* indicates P < 0.05.

300

301 Figure. 4. Putative reductases and oxidases of ubiquinone (UQ) predicted from the *V.*  
302 *cholerae* O395N1 and N16961 genomes are shown. Green represents the components  
303 present both in *V. cholerae* and human ETC. Orange represents the components that  
304 are not present in human ETC. The UQ reductase activity of NQR (VC2290-95) is  
305 coupled by the NADH oxidation and sodium extrusion activity. The UQ reductase  
306 activities of succinate dehydrogenase (SDH) (VC2088-91) and glycerol-3-phosphate  
307 dehydrogenase (GlpD) (VCA0657) are coupled to the oxidation of succinate and  
308 glycerol-3-P to fumarate and dehydroxyacetone-P, respectively. Other bacteria-specific  
309 respiration-linked dehydrogenases [such as Ndh2 (VC1890), L-lactate dehydrogenase  
310 (VCA0984), and D-amino acid dehydrogenase (VC0786)] are shown collectively (DHs).  
311 The *bd*-type cytochrome (*bd* cyt) oxidase-1 (VC1843-44) and oxidase-2 (VCA0872-73)  
312 oxidize the reduced form of UQ coupled to oxygen reduction and proton efflux activities.  
313 The ubiquinol-cytochrome C reductase (Fe/S bc1) (VC0573-75) also oxidizes the  
314 reduced form of UQ and the reaction is coupled with the cytochrome c4 (C) reduction  
315 and proton efflux activities. The reduced form of C is oxidized by cytochrome C (cytC)  
316 oxidase and the reaction is coupled to oxygen reduction and proton efflux activities.